Israeli-based specialist pharmaceutical firm Foamix Pharmaceutical is set to initiate a third Phase III clinical trial in the US to investigate FMX101 for the treatment of moderate-to-severe acne.

The additional Phase III trial will be based on the results obtained from two prior Phase III 04 and 05 trials.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FMX101 is a 4% minocycline foam being developed for the treatment of moderate-to-severe acne.

The third Phase III trial will evaluate FMX101 for a period of 12 weeks in approximately 1,500 patients at 80 clinical sites.

The co-primary efficacy endpoints are mean change of inflammatory lesion count from baseline and proportion of patients with improvement.

See Also:

Foamix chief executive officer Dov Tamarkin said: "Based on our analysis of the efficacy results from Trials 04 and 05, we plan to conduct a third trial to validate the results, with the same co-primary endpoints and enrolment criteria but with a substantially increased sample size.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We plan to conduct a third trial to validate the results, with the same co-primary endpoints and enrolment criteria but with a substantially increased sample size."

"We intend to begin enrolling patients in this third trial mid-year."

The top-line results from the prior double-blind, randomised, placebo-controlled Phase III trials were found to be favourable.

Conducted in a total of 961 patients over 12 weeks, the trials showed that FMX101 was safe and well tolerated, with no drug-related serious adverse events.

The co-primary endpoints of the trials were similar to that of the third trial, while the secondary endpoints included measure of decrease in non-inflammatory lesion count at week 12 and percentage changes in the inflammatory lesion count at weeks three, six, nine and 12.

Foamix plans to submit a new drug application (NDA) for FMX101 in the second half of next year, based on the results from the third Phase III trial.